| Description | Tavolixizumab (also known as MEDI 0562 and Tavolimab) is a human monoclonal antibody targeting TNFRSF4 (TNF receptor superfamily member 4), utilized in cancer immunology studies [1]. |
| Synonyms | MEDI 0562, Tavolimab |
| molecular weight | N/A |
| CAS | 1635395-25-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 years |